Rheumatoid Arthritis Basic Science Studies

You have full text access to this OnlineOpen article

Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides†

  1. Linda Mathsson1,
  2. Mohammed Mullazehi1,
  3. Marius C. Wick2,5,
  4. Olof Sjöberg1,
  5. Ronald van Vollenhoven3,
  6. Lars Klareskog3,‡,
  7. Johan Rönnelid4,6,*

Article first published online: 28 DEC 2007

DOI: 10.1002/art.23188

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 58, Issue 1, pages 36–45, January 2008

Additional Information

How to Cite

Mathsson, L., Mullazehi, M., Wick, M. C., Sjöberg, O., van Vollenhoven, R., Klareskog, L. and Rönnelid, J. (2008), Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis & Rheumatism, 58: 36–45. doi: 10.1002/art.23188

Author Information

  1. 1

    Uppsala University, Uppsala, Sweden

  2. 2

    Karolinska Institute, Stockholm, Sweden

  3. 3

    Karolinska Institute, Stockholm, Sweden

  4. 4

    Uppsala University, Uppsala, Sweden

  5. 5

    Innsbruck Medical University, Innsbruck, Austria

  6. 6

    Karolinska Institute, Stockholm, Sweden

  1. ‡

    Dr. Klareskog has received consulting fees, speaking fees, and/or honoraria (less than $10,000 each) from Wyeth, Schering-Plough, Bristol-Myers Squibb, Abbott, Roche, and Amgen. Dr. Rönnelid has received speaking fees (less than $10,000 each) from Schering-Plough, Wyeth, Pfizer, and Roche.

*Unit of Clinical Immunology, Rudbeck Laboratory C5, Uppsala University, SE-751 85 Uppsala, Sweden

  1. †

    Orgentec Inc. supplied anti-MCV kits for the study.

Publication History

  1. Issue published online: 28 DEC 2007
  2. Article first published online: 28 DEC 2007
  3. Manuscript Accepted: 7 SEP 2007
  4. Manuscript Received: 26 NOV 2006

Funded by

  • Swedish Fund for Research Without Animal Experiments
  • Agnes and Mac Rudberg Foundation
  • King Gustav V's 80-Year Fund
  • Signe and Reinhold Sund's Foundation for Rheumatological Research
  • Swedish Rheumatism Association

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (239K)

REFERENCES

  • 1
    Van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002; 4: 87–93.
  • 2
    Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 2002; 4 Suppl 2: S1–5.
  • 3
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 4
    Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 273–81.
  • 5
    Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155–63.
    Direct Link:
  • 6
    Hueber W, Hassfeld W, Smolen JS, Steiner G. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 155–9.
  • 7
    Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2: 236–43.
  • 8
    El-Gabalawy HS, Wilkins JA. Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther 2004; 6: 86–9.
  • 9
    Hayem G, Chazerain P, Combe B, Elias A, Haim T, Nicaise P, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999; 26: 7–13.
  • 10
    Boire G, Cossette P, de Brum-Fernandes AJ, Liang P, Niyonsenga T, Zhou ZJ, et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005; 7: R592–603.
  • 11
    Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994; 21: 1027–33.
  • 12
    Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6: R142–50.
  • 13
    Menard HA, Lapointe E, Rochdi MD, Zhou ZJ. Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000; 2: 429–32.
  • 14
    Egerer K, Bang H, Lathke K, Gauliard A, Feist E, Rudulph PE, et al. A new powerful marker for the diagnosis and prognosis of rheumatoid arthritis - anti-CMV (anti-citrullinated vimentin mutated) antibodies [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S118.
  • 15
    Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R119.
  • 16
    Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, et al. Longitudinal analysis of anti-citrullinated protein/peptide antibodies (anti-CP) during 5 year follow-up in early rheumatoid arthritis: anti-CP status is a stable phenotype that predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005; 64: 1744–9.
  • 17
    Mullazehi M, Mathsson L, Lampa J, Ronnelid J. High anti-collagen type II antibody levels and induction of pro-inflammatory cytokines by anti-collagen antibody containing immune complexes in vitro characterize a distinct RA phenotype associated with acute inflammation at the time of disease onset. Ann Rheum Dis 2007; 66: 537–41.
  • 18
    Bang H, Egerer K, Gauliard A, Luthke K, Rudulph PE, Fredenhagen G, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 2503–11.
    Direct Link:
  • 19
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977; 18: 481–91.
  • 20
    Wick M, Peloschek P, Bogl K, Graninger W, Smolen JS, Kainberger F. The “X-Ray RheumaCoach” software: a novel tool for enhancing the efficacy and accelerating radiological quantification in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 579–82.
  • 21
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 22
    Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis: use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988; 17: 263–71.
  • 23
    Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004; 31: 1829–33.
  • 24
    Kasapcopur O, Altun S, Aslan M, Karaarslan S, Kamburoglu-Goksel A, Saribas S, et al. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004; 63: 1687–9.
  • 25
    Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005; 32: 511–5.
  • 26
    Vander Cruyssen B, Hoffman IE, Zmierczak H, Van den Berghe M, Kruithof E, De Rycke L, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1145–9.
  • 27
    Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 2005; 44: 1056–60.
  • 28
    Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J Immunol 2001; 166: 4177–84.
  • 29
    Kinloch A, Tatzer V, Wait R, Peston D, Lundberg K, Donatien P, et al. Identification of citrullinated α-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1421–9.
  • 30
    Burkhardt H, Sehnert B, Bockermann R, Engstrom A, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005; 35: 1643–52.
    Direct Link:
View Full Article (HTML) Get PDF (239K)